Key Details
Price
$1.75Annual Revenue
$2.16 MAnnual EPS
-$572.80Annual ROE
-279.79%Beta
2.00Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
N/ARecent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 14, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
London, United Kingdom--(Newsfile Corp. - November 12, 2024) - Akanda Corp. (NASDAQ: AKAN) (the "Company" or "Akanda"), today announced that it expects to implement a 1-for-2 reverse stock split of the Company's common shares effective November 14, 2024. The reverse stock split was previously approved by the Company's shareholders on March 22, 2024 and Board of Directors on October 25, 2024 and will begin trading on an adjusted basis giving effect to the reverse stock split at the opening of market on November 14, 2024 under the existing ticker symbol "AKAN".
London, United Kingdom--(Newsfile Corp. - October 4, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, entered into an underwriting agreement (the "Underwriting Agreement") with Univest Securities, LLC ("Univest") as the underwriter in connection with the issuance and sale by the Company in an underwritten public offering (the "Offering") of 258,940 of the Company's Common Shares, no par value per share (the "Common Shares" and, such number of Common Shares issued and sold in the Offering, the "Offered Shares"), at a purchase price of $1.00 per Offered Share, and 1,241,060 pre-funded warrants to purchase 1,241,060 Common Shares at a purchase price of each pre-funded warrant equal to the price at which one Common Share is sold in the Offering, minus $0.0001, and the exercise price of each pre-funded warrant is $0.0001 per share (the "Pre-Funded Warrants" and, such number of Pre-Funded Warrants issued and sold in the Offering, the "Offered Pre-Funded Warrants"), pursuant to the Company's effective registration statement on Form F-1 (File No. 333-281945) and a related preliminary prospectus, together with the related final prospectus dated as of October 2, 2024 (such registration statement, preliminary prospectus and the final prospectus, collectively, the "Registration Statement"), filed with the Securities and Exchange Commission.
London, United Kingdom--(Newsfile Corp. - September 16, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), a global cannabis company, is excited to announce that it has obtained a license for hemp cultivation in Canada. This license is directly tied to Akanda's previously announced agreement with 1107385 B.C.
London, United Kingdom--(Newsfile Corp. - June 14, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced that it has successfully completed sales of its securities under its existing Form F-3 shelf registration. The shelf registration statement had a $5 million capacity and allowed the Company to raise cash by selling stock and warrants into the open market.
Akanda (NASDAQ: AKAN ) stock is rocketing higher on Friday alongside heavy pre-market trading of the cannabis company's shares. This has more than 6.3 million shares of AKAN stock changing hands as of this writing.
London, United Kingdom--(Newsfile Corp. - May 20, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced that it has closed its previously announced second registered direct offering for the sale and issuance of 2,491,381common shares at a purchase price of $0.1031 and 12,057,600 pre-funded warrants to purchase 12,057,600 common shares at $0.103 per share, priced at the Minimum Price under the Nasdaq rules. The pre-funded warrants are immediately exercisable for $0.0001 per share and may be exercised at any time until all of the pre-funded warrants are exercised in full, subject to certain beneficial ownership limitations as set forth in the pre-funded warrant.
In London, United Kingdom, Akanda Corp. (NASDAQ: AKAN) announced today that it has entered into a second securities purchase agreement with an accredited investor. The investor has agreed to purchase 2,491,381 common shares at a price of $0.1031 per share and 12,057,600 pre-funded warrants to purchase common shares at $0.103 per share in a registered direct offering priced at the Minimum Price under Nasdaq rules. The pre-funded warrants can be exercised immediately at an exercise price of $0.0001 and are subject to certain beneficial ownership limitations outlined in the agreement.
Akanda Corp. (NASDAQ: AKAN) has successfully completed its registered direct offering, selling 2,491,381 common shares at $0.1031 per share and 21,756,922 pre-funded warrants at a price of $0.103 per share. The pre-funded warrants can be exercised for $0.0001 per share at any time, subject to certain ownership limitations.
Akanda Corp. has announced a securities purchase agreement with an accredited investor to buy 2,491,381 common shares and 21,756,922 pre-funded warrants in a registered direct offering priced at the minimum price under Nasdaq rules. The pre-funded warrants can be exercised immediately at a price of $0.0001 and have certain limitations on beneficial ownership.
Akanda (NASDAQ: AKAN) stock is rising on Friday despite receiving a non-compliance notice from the Nasdaq Exchange due to not meeting the minimum stockholders' equity requirement to stay listed.
FAQ
- What is the primary business of AKANDA?
- What is the ticker symbol for AKANDA?
- Does AKANDA pay dividends?
- What sector is AKANDA in?
- What industry is AKANDA in?
- What country is AKANDA based in?
- When did AKANDA go public?
- Is AKANDA in the S&P 500?
- Is AKANDA in the NASDAQ 100?
- Is AKANDA in the Dow Jones?
- When does AKANDA report earnings?